US EditionNous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers: A Phase 1b/2 Trial
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Early Evidence of Preventive Cancer Vaccine for Lynch Syndrome
An investigational immunotherapy vaccine for people with Lynch syndrome has shown early promise in a Phase Ib/II study at provoking an immune response that intercepts the development of cancer. The findings, published in Nature Medicine, showed that NOUS-209, an off-the-shelf cancer vaccine designed to train the immune system to recognize and eliminate precancerous and cancerous cells before invasive disease develops, showed that it safely induc…
An experimental vaccine managed to specifically stimulate the immune system in people with Lynch syndrome, an inherited condition that raises the risk of colorectal cancer and other tumors, according to the initial results of a clinical trial published in the journal Nature Medicine. Lynch syndrome is caused by mutations in responsible genes [...] The post An experimental vaccine active defenses against hereditary colon cancer appeared first on …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
